Seeking Alpha

Baxter (BAX) confirms it's received a complete response letter from the FDA delaying the...

Baxter (BAX) confirms it's received a complete response letter from the FDA delaying the approval of its investigational product HyQ. More specifically, the agency says it's seeking additional preclinical data focusing on issues related to non-neutralizing antibodies and the possible effects they have on reproduction, development and fertility. HyQ, which is in development with Halozyme Therapeutics (HALO), is a treatment that aims to allow physicians to tailor antibody drug therapy to the needs of patients with immune-system disorders. BAX -0.6%, HALO -54% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs